Teladoc Health Q3 2024 Financial Results

Overview
Teladoc Health (NYSE: TDOC) reported its Q3 2024 financial results, revealing a 3% year-over-year decrease in consolidated revenue, amounting to $641 million. While overall revenue decreased, the Integrated Care segment saw a slight revenue increase of 2.5%, totaling $384 million. Conversely, the BetterHelp segment experienced a 10% decline, generating $257 million in revenue.

Adjusted EBITDA for the quarter was $83.3 million (down 6% year-over-year, with a 13% margin), and the net loss per share improved to $0.19 from a loss of $0.35 in Q3 2023. Free cash flow rose by 16% to $79 million, with the company holding over $1.2 billion in cash.

Key Takeaways

• Q3 consolidated revenue fell by 3% to $641 million.
• Adjusted EBITDA decreased by 6% to $83.3 million (13% margin).
• Improved net loss per share from $0.35 to $0.19.
• Free cash flow increased by 16%.
• Integrated Care segment revenue grew by 2.5% with rising membership.
• BetterHelp revenue dropped by 10% due to lower user additions and stable average revenue per user.
• Q4 Integrated Care revenue expected to be flat to up 2.5%.
• No formal guidance for BetterHelp due to uncertainties.

Company Outlook

• Q4 Integrated Care revenue is projected to be flat to up 2.5%.
• Adjusted EBITDA margins for Q4 are expected between 12.25% and 13.75%.
• U.S. Integrated Care member count expected to reach 93.5 to 94.5 million by year-end.
• Full-year adjusted EBITDA margin expected to be 14.9% to 15.3%.
• For 2025, the company targets revenue growth in line with Q4 trends while focusing on margin maintenance and cost management.

Bearish Highlights

• Poor performance of the BetterHelp segment with revenue decline and increased advertising costs.
• Projected revenue growth for 2025 is flat to 2.5%, which is lower than the expected 2024 total guidance.
• Retention rates, while above 90%, have decreased compared to historical levels.

Bullish Highlights

• The Integrated Care segment showed strength with revenue growth and surpassed membership expectations.
• Chronic Care program enrollment increased to 1.18 million.
• International Integrated Care segment reported high-teens revenue growth.

Misses

• Decline in overall revenue and adjusted EBITDA.
• Significant drop in BetterHelp segment adjusted EBITDA from $26 million to $15.2 million.

Q&A Highlights

• Management is prioritizing enrollment growth, increased visit volume, and pricing adjustments to support revenue growth.
• A strategic reduction in advertising spending is planned for Q4.
• Annual technology and development spending is estimated at $425 million to $450 million with a focus on optimizing expenses.

In conclusion, while Teladoc Health faces challenges in the virtual care market, the company is actively managing its resources and streamlining operations to enhance future performance. With a robust cash position, Teladoc aims to retire a convertible bond due in June 2025 and continues to invest in strategic priorities.

InvestingPro Insights

Teladoc Health's financial results indicate a company managing through difficult market conditions. As of Q2 2024, the company's market capitalization is $1.54 billion, with annual revenue at $2.61 billion and a growth rate of 3.1%. Investors should note that Teladoc is currently not profitable but has a strong free cash flow yield.

Financial Metrics

• Price-to-book ratio of 1.03 suggests the stock trades near book value.
• High EBITDA valuation multiple indicates the market's expectations for future growth.
• Net income is expected to decline this year, aligning with the company's cautious outlook, especially regarding BetterHelp.

InvestingPro provides additional insights for a deeper understanding of Teladoc's financial position and market prospects.

Full Transcript – Teladoc Inc (TDOC) Q3 2024 Conference Call

Operator

Hello and welcome to the Teladoc Health Third Quarter 2024 Call. My name is Alex, and I'll be coordinating the call today.

Michael Minchak

Thank you, and good afternoon. Today, after the market closed, we issued a press release announcing our third quarter 2024 financial results. This press release and accompanying slide presentation are available in the Investor Relations section of the teladochealth.com website. On this call to discuss the results are Chuck Divita, Chief Executive Officer; and Mala Murthy, Chief Financial Officer.

Chuck Divita

Thanks, Mike, and good afternoon, everyone. We're pleased with our results for the quarter, including Integrated Care revenue, adjusted EBITDA, and membership above guidance.

… (transcript continues)